Another group [7] that recently investigated the efficacy and safety of different antithrombotic strategies in patients with AF undergoing interventions concluded that for those undergoing coronary interventions, treatment with apixaban + P2Y12 inhibitors was associated with lowest bleeding rate compared with other regimens, including other DOACs + P2Y12 inhibitors. The gene discussed is P2RY12; the disease is atrial fibrillation.